Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03581032 Recruiting - Heart Failure Clinical Trials

Optimization of Cardiac Pacing Using CardioMEMS

Start date: March 1, 2017
Phase:
Study type: Observational

This study is designed to determine if a simplified technique for cardiac device reprogramming using pulmonary artery pressure (PAP) data in the acute setting holds promise to improve subjective assessments of patient quality of life (QOL), objective measurements of functional capacity, and specific systolic and diastolic echocardiographic indices.

NCT ID: NCT03579914 Recruiting - Heart Failure Clinical Trials

Effect of Intravenous Metoprolol Combining RIPC on Myocardial Protection in STEMI Patients

Start date: November 28, 2017
Phase: Phase 2
Study type: Interventional

This study is aim to discover the difference of protective effect on comparing Metoprolol administration before cardiac reperfusion combined with remote ischemic post-conditioning (RIPC) in patients with anterior STEMI in China. This study sought to find possible strategy on ameliorate the patients with anterior STEMI in China through the mechanisms on cardiac protection before cardiac reperfusion.

NCT ID: NCT03576261 Recruiting - Heart Failure Clinical Trials

Heart Failure and Hemodynamic Stability During Anesthesia Induction

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

The study aim is to investigate whether preoperative heart failure has impact on hemodynamic stability during anesthesia induction by target controlled infusion of anesthesia (TCI) in non-cardiac, non-morbidly obese surgery.

NCT ID: NCT03574662 Recruiting - Heart Failure Clinical Trials

The Utility of Focused Frailty Interventions on Patients With Advanced Heart Failure

Start date: May 4, 2018
Phase: N/A
Study type: Interventional

The Researchers are doing this study to find out if the cardiac rehabilitation program can improve measurements of frailty and improve independence, functional abilities, and feelings about health. Frailty can be measured by weakness (as measured by hand grip strength), slowness (as measured by walking speed), low level of physical activity, low energy or self-reported exhaustion, and unintentional weight loss.

NCT ID: NCT03573869 Recruiting - Atrial Fibrillation Clinical Trials

Atrial FIbrillation Treatment With Cryoballoon in Heart failurE (AFICHE)

AFICHE
Start date: June 1, 2018
Phase: N/A
Study type: Interventional

In this study 404 patients with heart failure and an ejection fraction of 0.40 or less, with paroxysmal atrial fibrillation, will be randomly assigned to standard treatment or standard treatment plus a session of cryoballoon ablation (left atrial balloon cryoablation for pulmonary vein isolation). All patients with either have an ICD or CRT-D/P device implanted or an implantable electrocardiographic monitoring device. The primary study endpoint will be the time to AF burden exceeding 1% over any 30-day period (calculated as the ratio of time spent in AF over total time).16 This AF burden corresponds to 7.2 hours per month. A powered secondary endpoint will be the time to the composite of all-cause mortality and unplanned hospitalization for heart failure.

NCT ID: NCT03573427 Recruiting - Clinical trials for Left Ventricular Dysfunction

LV Endocardial CRT for Patients With Intermediate QRS Width

EndoCRT
Start date: April 28, 2016
Phase:
Study type: Observational

This pilot study is designed as a multi-centre cohort study determining the degree of LV reverse remodeling in patients with intermediate QRS widths (120-149ms) who undergo CRT implant with transseptal LV leads, and comparing to the average expected reverse remodeling rate in patients with standard transvenous coronary sinus leads and QRS widths ≥150ms.

NCT ID: NCT03560206 Recruiting - Heart Failure Clinical Trials

Effects of Family Sodium Watcher Program on Outcomes in Heart Failure Patient-Family Caregiver Dyads

FAMSWAP
Start date: March 1, 2015
Phase: N/A
Study type: Interventional

The Family Sodium Watcher program in this study is designed to improve adherence to a sodium restricted diet in patients with HF using strategies that educate both patients and family caregivers about sodium monitoring and that stress a gradual progressive adaptation to low sodium food for both patients and family caregivers.

NCT ID: NCT03553303 Recruiting - Clinical trials for Heart Failure, Systolic

Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin

Start date: July 2018
Phase: Phase 4
Study type: Interventional

The study measure multiple neurohormones in patients with heart failure being treated with Sacubitril/Valsartan in increasing doses over an 8 week period.

NCT ID: NCT03552679 Recruiting - Right Heart Failure Clinical Trials

Serial Multiparametric Evaluation of Right Ventricular Function After Left Ventricular Assist Device Implantation

EuroEchoVAD
Start date: June 2018
Phase:
Study type: Observational [Patient Registry]

The primary purpose of this study is to investigate the evolution of Right Ventricular (RV) function before and after left ventricular assist device (LVAD) implantation, using novel echocardiographic quantification of RV size and function in combination with comprehensive hemodynamic, laboratory and clinical parameters. The findings of the study will enhance prediction of early and late development of postoperative right-sided heart failure (RHF) and subsequent mortality and morbidity. The secondary purpose of the study is to combine echocardiographic, hemodynamic, laboratory, and clinical data to define optimal management strategies of RHF after LVAD implantation.

NCT ID: NCT03547583 Recruiting - Clinical trials for Chronic Heart Failure With Preserved Ejection Fraction

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

VITALITY-HFpEF
Start date: June 15, 2018
Phase: Phase 2
Study type: Interventional

The primary hypothesis in this trial is that the treatment with vericiguat 10 mg or 15 mg in patients with HFpEF improves the KCCQ PLS (Kansas City Cardiomyopathy Questionnaire Physical limitation score) compared to placebo after 24 weeks of treatment.